Prolactin serum levels correlate with inflammatory status in drug-naïve first-episode schizophrenia

References

• Adamson AD, Friedrichsen S, Semprini S, Harper CV, Mullins JJ, White MR, et al. 2008. Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling. Endocrinology 149:687–694.
   PubMedGoogle Scholar
• Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, Riecher-Rossler A. 2010. Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 34:1342–1344.
   PubMed Web of Science ®Google Scholar
• Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. 2006. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. Cell Biochem Funct 24:353–356.
   PubMed Web of Science ®Google Scholar
• Bar-Shai M, Hasnis E, Wiener-Megnazi Z, Reznick AZ. 2006. The role of reactive nitrogen species and cigarette smoke in activation of transcription factor NF-kappaB and implication to inflammatory processes. J Physiol Pharmacol: Offic J Polish Physiol Soc 57(Suppl 4):39–44.
   Google Scholar
• Bergink V, Gibney SM, Drexhage HA. 2014. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 75:324–331.
   PubMed Web of Science ®Google Scholar
• Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. 1998. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268.
   PubMed Web of Science ®Google Scholar
• Bostwick JR, Guthrie SK, Ellingrod VL. 2009. Antipsychotic- induced hyperprolactinemia. Pharmacotherapy 29:64–73.
   PubMed Web of Science ®Google Scholar
• Brandebourg T, Hugo E, Ben-Jonathan N. 2007. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9:464–476.
   PubMed Web of Science ®Google Scholar
• Byerly M, Suppes T, Tran QV, Baker RA. 2007. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27:639–661.
   PubMed Web of Science ®Google Scholar
• Caracci G, Ananthamoorthy R. 1999. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J Clin Psychopharmacol 19:194–196.
   PubMed Web of Science ®Google Scholar
• Cejkova P, Fojtikova M, Cerna M. 2009. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 9:23–27.
   PubMed Web of Science ®Google Scholar
• Chen C, Lu FC, Department of Disease Control Ministry of Health PRC 2004. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci: BES 17(Suppl):1–36.
   Google Scholar
• David SR, Taylor CC, Kinon BJ, Breier A. 2000. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085–1096.
   PubMed Web of Science ®Google Scholar
• Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, et al. 2010. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 118:211–217.
   PubMed Web of Science ®Google Scholar
• Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. 2007. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149: 267–271.
   PubMed Web of Science ®Google Scholar
• Fan X, Song X. 2013. Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics. Evidence-based Mental Health 16:10.
   Google Scholar
• Flint DJ, Binart N, Kopchick J, Kelly P. 2003. Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 6:97–102.
   PubMedGoogle Scholar
• Flower L, Gray R, Pinkney J, Mohamed-Ali V. 2003. Stimulation of interleukin-6 release by interleukin-1beta from isolated human adipocytes. Cytokine 21:32–37.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, et al. 2010. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res 176: 99–102.
   PubMed Web of Science ®Google Scholar
• Friedrichsen S, Harper CV, Semprini S, Wilding M, Adamson AD, Spiller DG, et al. 2006. Tumor necrosis factor-alpha activates the human prolactin gene promoter via nuclear factor-kappaB signaling. Endocrinology 147:773–781.
   Google Scholar
• Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, et al. 2012. Prolactin concentrations in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Res 134:16–19.
   PubMed Web of Science ®Google Scholar
• Guo Q, Yang Y, Mu Y, Lu J, Pan C, Dou J, et al. 2013. Pituitary stalk interruption syndrome in Chinese people: clinical characteristic analysis of 55 cases. PLoS One 8:e53579.
   Google Scholar
• Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. 2011. Prolactin and autoimmunity. Clin Rev Allergy Immunol 40:50–59.
   PubMed Web of Science ®Google Scholar
• Jaroenporn S, Nagaoka K, Kasahara C, Ohta R, Watanabe G, Taya K. 2007. Physiological roles of prolactin in the adrenocortical response to acute restraint stress. Endocr J 54:703–711.
   PubMedGoogle Scholar
• Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. 1998. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32:9–15.
   PubMed Web of Science ®Google Scholar
• Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F, et al. 2002. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54:281–291.
   PubMed Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V. 2004. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry: J Ment Sci 184:503–508.
   PubMed Web of Science ®Google Scholar
• Messini CI, Dafopoulos K, Chalvatzas N, Georgoulias P, Anifandis G, Messinis IE. 2010. Effect of ghrelin and thyrotropin-releasing hormone on prolactin secretion in normal women. Horm Metab Res 42:204–208.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70: 663–671.
   PubMed Web of Science ®Google Scholar
• Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. 2000. The immune system and schizophrenia. An integrative view. Ann NY Acad Sci 917:456–467.
   PubMed Web of Science ®Google Scholar
• Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. 1997. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?Schizophr Res 26:227–233.
   PubMed Web of Science ®Google Scholar
• Oride A, Kanasaki H, Purwana IN, Miyazaki K. 2009. Possible involvement of mitogen-activated protein kinase phosphatase-1 (MKP-1) in thyrotropin-releasing hormone (TRH)-induced prolactin gene expression. Biochem Biophys Res Commun 382:663–667.
   Google Scholar
• Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, et al. 2008. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol (Oxford) 22: 98–103.
   PubMedGoogle Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Lohr JB. 1994. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 90:311–315.
   PubMedGoogle Scholar
• Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P, et al. 2013. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med 43:2571–2582.
   PubMed Web of Science ®Google Scholar
• Runeson BS, Rich CL. 1994. Diagnostic and statistical manual of mental disorders (3rd ed, DSM-III). Adaptive functioning in young Swedish suicides.Ann Clin Psychiatry: Offic J Am Acad Clin Psychiatrists 6:181–183.
   Google Scholar
• Schwarz MJ, Chiang S, Muller N, Ackenheil M. 2001. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 15:340–370.
   PubMed Web of Science ®Google Scholar
• Shiwach RS, Carmody TJ. 1998. Prolactogenic effects of risperidone in male patients – a preliminary study. Acta Psychiatr Scand 98:81–83.
   PubMedGoogle Scholar
• Sirota P, Meiman M, Herschko R, Bessler H. 2005. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 134:151–159.
   PubMedGoogle Scholar
• Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. 2009. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65:481–488.
   PubMed Web of Science ®Google Scholar
• Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook RD, et al. 2000. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br J Cancer 82:1577–1584.
   Google Scholar
• Wu W, Sun M, Zhang HP, Chen T, Wu R, Liu C, et al. 2014. Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation. Gut.
   Google Scholar